{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:43:48Z","timestamp":1792759428320,"version":"4.5.0"},"reference-count":223,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"DOI":"10.1038\/s41582-026-01274-z","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:36:28Z","timestamp":1792751788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mitochondrial dysfunction in neurology: biomarkers and clinical implications"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7862-6743","authenticated-orcid":false,"given":"Elena","family":"Rossini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6123-4551","authenticated-orcid":false,"given":"Robert D. S.","family":"Pitceathly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pizzamiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"1274_CR1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214618","volume":"106","author":"E Benarroch","year":"2026","unstructured":"Benarroch, E. What are the roles of mitochondrial stress responses and mitohormesis in neurodegenerative disorders? Neurology 106, e214618 (2026).","journal-title":"Neurology"},{"key":"1274_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.semcdb.2017.09.021","volume":"76","author":"S Schorr","year":"2018","unstructured":"Schorr, S. & Van Der Laan, M. Integrative functions of the mitochondrial contact site and cristae organizing system. Semin. Cell Dev. Biol. 76, 191\u2013200 (2018).","journal-title":"Semin. Cell Dev. Biol."},{"key":"1274_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41556-018-0124-1","volume":"20","author":"JB Spinelli","year":"2018","unstructured":"Spinelli, J. B. & Haigis, M. C. The multifaceted contributions of mitochondria to cellular metabolism. Nat. Cell Biol. 20, 745\u2013754 (2018).","journal-title":"Nat. Cell Biol."},{"key":"1274_CR4","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1016\/j.cell.2024.04.037","volume":"187","author":"A Suomalainen","year":"2024","unstructured":"Suomalainen, A. & Nunnari, J. Mitochondria at the crossroads of health and disease. Cell 187, 2601\u20132627 (2024).","journal-title":"Cell"},{"key":"1274_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.80","volume":"2","author":"GS Gorman","year":"2016","unstructured":"Gorman, G. S. et al. Mitochondrial diseases. Nat. Rev. Dis. Primers 2, 16080 (2016).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1274_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-024-01839-8","volume":"9","author":"Y Zong","year":"2024","unstructured":"Zong, Y. et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct. Target. Ther. 9, 124 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1274_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000446586","volume":"7","author":"DM Niyazov","year":"2016","unstructured":"Niyazov, D. M., Kahler, S. G. & Frye, R. E. Primary mitochondrial disease and secondary mitochondrial dysfunction: importance of distinction for diagnosis and treatment. Mol. Syndromol. 7, 122\u2013137 (2016).","journal-title":"Mol. Syndromol."},{"key":"1274_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/jcm7020016","volume":"7","author":"J Finsterer","year":"2018","unstructured":"Finsterer, J. & Zarrouk-Mahjoub, S. Biomarkers for detecting mitochondrial disorders. J. Clin. Med. 7, 16 (2018).","journal-title":"J. Clin. Med."},{"key":"1274_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00325","volume":"21","author":"BJ Shayota","year":"2024","unstructured":"Shayota, B. J. Biomarkers of mitochondrial disorders. Neurotherapeutics 21, e00325 (2024).","journal-title":"Neurotherapeutics"},{"key":"1274_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1042\/EBC20170111","volume":"62","author":"S Boenzi","year":"2018","unstructured":"Boenzi, S. & Diodato, D. Biomarkers for mitochondrial energy metabolism diseases. Essays Biochem. 62, 443\u2013454 (2018).","journal-title":"Essays Biochem."},{"key":"1274_CR11","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/brainsci11030398","volume":"11","author":"A Lupica","year":"2021","unstructured":"Lupica, A. et al. Inherited neuromuscular disorders: which role for serum biomarkers? Brain Sci. 11, 398 (2021).","journal-title":"Brain Sci."},{"key":"1274_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/B978-0-12-821751-1.00006-3","volume":"194","author":"A Suomalainen","year":"2023","unstructured":"Suomalainen, A. Blood biomarkers of mitochondrial disease-one for all or all for one? Handb. Clin. Neurol. 194, 251\u2013257 (2023).","journal-title":"Handb. Clin. Neurol."},{"key":"1274_CR13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s10545-018-0224-x","volume":"41","author":"M Batllori","year":"2018","unstructured":"Batllori, M. et al. Cerebrospinal fluid monoamines, pterins, and folate in patients with mitochondrial diseases: systematic review and hospital experience. J. Inherit. Metab. Dis. 41, 1147\u20131158 (2018).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1274_CR14","first-page":"5968","volume":"104","author":"CR Vissing","year":"2019","unstructured":"Vissing, C. R., Dun\u00f8, M., Wibrand, F., Christensen, M. & Vissing, J. Hydroxylated long-chain acylcarnitines are biomarkers of mitochondrial myopathy. J. Clin. Endocrinol. Metab. 104, 5968\u20135976 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1274_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ymgme.2012.11.283","volume":"108","author":"S Pajares","year":"2013","unstructured":"Pajares, S., Arias, A., Garc\u00eda-Villoria, J., Briones, P. & Ribes, A. Role of creatine as biomarker of mitochondrial diseases. Mol. Genet. Metab. 108, 119\u2013124 (2013).","journal-title":"Mol. Genet. Metab."},{"key":"1274_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejpn.2010.10.001","volume":"15","author":"M Magner","year":"2011","unstructured":"Magner, M. et al. Elevated CSF-lactate is a reliable marker of mitochondrial disorders in children even after brief seizures. Eur. J. Paediatr. Neurol. 15, 101\u2013108 (2011).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"1274_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mito.2021.07.002","volume":"60","author":"N L\u00f8kken","year":"2021","unstructured":"L\u00f8kken, N., Skriver, S. V., Khawajazada, T., Storgaard, J. H. & Vissing, J. Plasma lactate responses during and after submaximal handgrip exercise are not diagnostically helpful in mitochondrial myopathy. Mitochondrion 60, 21\u201326 (2021).","journal-title":"Mitochondrion"},{"key":"1274_CR18","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.2169\/internalmedicine.8629-21","volume":"61","author":"M Kurihara","year":"2022","unstructured":"Kurihara, M. et al. Diagnostic values of venous peak lactate, lactate-to-pyruvate ratio, and fold increase in lactate from baseline in aerobic exercise tests in patients with mitochondrial diseases. Intern. Med. 61, 1939\u20131946 (2022).","journal-title":"Intern. Med."},{"key":"1274_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.nmd.2013.05.007","volume":"23","author":"TD Jeppesen","year":"2013","unstructured":"Jeppesen, T. D., Orngreen, M. C., Van Hall, G. & Vissing, J. Lactate metabolism during exercise in patients with mitochondrial myopathy. Neuromuscul. Disord. 23, 629\u2013636 (2013).","journal-title":"Neuromuscul. Disord."},{"key":"1274_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/0887-8994(92)90007-L","volume":"8","author":"C-S Chi","year":"1992","unstructured":"Chi, C.-S., Mak, S.-C., Shian, W.-J. & Chen, C.-H. Oral glucose lactate stimulation test in mitochondrial diseases. Pediatr. Neurol. 8, 445\u2013449 (1992).","journal-title":"Pediatr. Neurol."},{"key":"1274_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.mito.2004.07.010","volume":"4","author":"BA Barshop","year":"2004","unstructured":"Barshop, B. A. Metabolomic approaches to mitochondrial disease: correlation of urine organic acids. Mitochondrion 4, 521\u2013527 (2004).","journal-title":"Mitochondrion"},{"key":"1274_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cca.2018.03.002","volume":"481","author":"M Semeraro","year":"2018","unstructured":"Semeraro, M. et al. The urinary organic acids profile in single large-scale mitochondrial DNA deletion disorders. Clin. Chim. Acta Int. J. Clin. Chem. 481, 156\u2013160 (2018).","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"1274_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1080\/10408363.2023.2166013","volume":"60","author":"AJ Paredes-Fuentes","year":"2023","unstructured":"Paredes-Fuentes, A. J., Oliva, C., Urreizti, R., Yubero, D. & Artuch, R. Laboratory testing for mitochondrial diseases: biomarkers for diagnosis and follow-up. Crit. Rev. Clin. Lab. Sci. 60, 270\u2013289 (2023).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"1274_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.braindev.2011.08.004","volume":"34","author":"K Yamada","year":"2012","unstructured":"Yamada, K. et al. Diagnostic accuracy of blood and CSF lactate in identifying children with mitochondrial diseases affecting the central nervous system. Brain Dev. 34, 92\u201397 (2012).","journal-title":"Brain Dev."},{"key":"1274_CR25","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.cmet.2020.04.008","volume":"31","author":"E Pirinen","year":"2020","unstructured":"Pirinen, E. et al. Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metab. 31, 1078\u20131090.e5 (2020).","journal-title":"Cell Metab."},{"key":"1274_CR26","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1212\/01.wnl.0000220197.36849.1e","volume":"66","author":"Y Koga","year":"2006","unstructured":"Koga, Y. et al. Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology 66, 1766\u20131769 (2006).","journal-title":"Neurology"},{"key":"1274_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.2283","volume":"12","author":"A Verma","year":"2024","unstructured":"Verma, A. et al. Amino acid ratio combinations as biomarkers for discriminating patients with pyruvate dehydrogenase complex deficiency from other inborn errors of metabolism. Mol. Genet. Genom. Med. 12, e2283 (2024).","journal-title":"Mol. Genet. Genom. Med."},{"key":"1274_CR28","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1474-4422(11)70155-7","volume":"10","author":"A Suomalainen","year":"2011","unstructured":"Suomalainen, A. et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol. 10, 806\u2013818 (2011).","journal-title":"Lancet Neurol."},{"key":"1274_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-2164-15-91","volume":"15","author":"SG Kalko","year":"2014","unstructured":"Kalko, S. G. et al. Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies. BMC Genom. 15, 91 (2014).","journal-title":"BMC Genom."},{"key":"1274_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/cen.12095","volume":"78","author":"YC Woo","year":"2013","unstructured":"Woo, Y. C., Xu, A., Wang, Y. & Lam, K. S. L. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin. Endocrinol. 78, 489\u2013496 (2013).","journal-title":"Clin. Endocrinol."},{"key":"1274_CR31","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1212\/WNL.0000000000003374","volume":"87","author":"JM Lehtonen","year":"2016","unstructured":"Lehtonen, J. M. et al. FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders. Neurology 87, 2290\u20132299 (2016).","journal-title":"Neurology"},{"key":"1274_CR32","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/acn3.51104","volume":"7","author":"Y Lin","year":"2020","unstructured":"Lin, Y. et al. Accuracy of FGF-21 and GDF-15 for the diagnosis of mitochondrial disorders: A meta-analysis. Ann. Clin. Transl. Neurol. 7, 1204\u20131213 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1274_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148709","volume":"11","author":"R Montero","year":"2016","unstructured":"Montero, R. et al. GDF-15 is elevated in children with mitochondrial diseases and is induced by mitochondrial dysfunction. PLoS ONE 11, e0148709 (2016).","journal-title":"PLoS ONE"},{"key":"1274_CR34","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jimd.12307","volume":"44","author":"JM Lehtonen","year":"2021","unstructured":"Lehtonen, J. M. et al. Diagnostic value of serum biomarkers FGF21 and GDF15 compared to muscle sample in mitochondrial disease. J. Inherit. Metab. Dis. 44, 469\u2013480 (2021).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1274_CR35","volume":"8","author":"JLK Van Hove","year":"2024","unstructured":"Van Hove, J. L. K. et al. Protein biomarkers GDF15 and FGF21 to differentiate mitochondrial hepatopathies from other pediatric liver diseases. Hepatol. Commun. 8, e0361 (2024).","journal-title":"Hepatol. Commun."},{"key":"1274_CR36","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.3390\/jcm12062435","volume":"12","author":"L Bermejo-Guerrero","year":"2023","unstructured":"Bermejo-Guerrero, L. et al. Serum GDF-15 levels accurately differentiate patients with primary mitochondrial myopathy, manifesting with exercise intolerance and fatigue, from patients with chronic fatigue syndrome. J. Clin. Med. 12, 2435 (2023).","journal-title":"J. Clin. Med."},{"key":"1274_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mito.2019.10.005","volume":"50","author":"NS Poulsen","year":"2020","unstructured":"Poulsen, N. S. et al. Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy. Mitochondrion 50, 35\u201341 (2020).","journal-title":"Mitochondrion"},{"key":"1274_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2021.12.001","volume":"135","author":"LG Riley","year":"2022","unstructured":"Riley, L. G. et al. FGF21 outperforms GDF15 as a diagnostic biomarker of mitochondrial disease in children. Mol. Genet. Metab. 135, 63\u201371 (2022).","journal-title":"Mol. Genet. Metab."},{"key":"1274_CR39","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/ana.24506","volume":"78","author":"S Yatsuga","year":"2015","unstructured":"Yatsuga, S. et al. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann. Neurol. 78, 814\u2013823 (2015).","journal-title":"Ann. Neurol."},{"key":"1274_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66940-8","volume":"10","author":"C Dominguez-Gonzalez","year":"2020","unstructured":"Dominguez-Gonzalez, C. et al. Growth differentiation factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy. Sci. Rep. 10, 10111 (2020).","journal-title":"Sci. Rep."},{"key":"1274_CR41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.mito.2021.10.008","volume":"62","author":"WHG Hubens","year":"2022","unstructured":"Hubens, W. H. G. et al. Blood biomarkers for assessment of mitochondrial dysfunction: an expert review. Mitochondrion 62, 187\u2013204 (2022).","journal-title":"Mitochondrion"},{"key":"1274_CR42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/acn3.532","volume":"5","author":"SJ Pickett","year":"2018","unstructured":"Pickett, S. J. et al. Phenotypic heterogeneity in m.3243A>G mitochondrial disease: the role of nuclear factors. Ann. Clin. Transl. Neurol. 5, 333\u2013345 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1274_CR43","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708262","volume":"10","author":"JP Grady","year":"2018","unstructured":"Grady, J. P. et al. mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. EMBO Mol. Med. 10, e8262 (2018).","journal-title":"EMBO Mol. Med."},{"key":"1274_CR44","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.4103\/0366-6999.216395","volume":"130","author":"C-Y Xia","year":"2017","unstructured":"Xia, C.-Y. et al. Reference intervals of mitochondrial DNA copy number in peripheral blood for Chinese minors and adults. Chin. Med. J. 130, 2435\u20132440 (2017).","journal-title":"Chin. Med. J."},{"key":"1274_CR45","first-page":"334","volume":"113","author":"C-S Liu","year":"2006","unstructured":"Liu, C.-S. et al. Alteration in the copy number of mitochondrial DNA in leukocytes of patients with mitochondrial encephalomyopathies. Acta Neurol. Scand. 113, 334\u2013341 (2006).","journal-title":"Acta Neurol. Scand."},{"key":"1274_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067146","volume":"8","author":"H Liu","year":"2013","unstructured":"Liu, H. et al. Wild-type mitochondrial DNA copy number in urinary cells as a useful marker for diagnosing severity of the mitochondrial diseases. PLoS ONE 8, e67146 (2013).","journal-title":"PLoS ONE"},{"key":"1274_CR47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.mito.2021.04.002","volume":"59","author":"C Trumpff","year":"2021","unstructured":"Trumpff, C. et al. Stress and circulating cell-free mitochondrial DNA: a systematic review of human studies, physiological considerations, and technical recommendations. Mitochondrion 59, 225\u2013245 (2021).","journal-title":"Mitochondrion"},{"key":"1274_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21984-w","volume":"12","author":"K Todkar","year":"2021","unstructured":"Todkar, K. et al. Selective packaging of mitochondrial proteins into extracellular vesicles prevents the release of mitochondrial DAMPs. Nat. Commun. 12, 1971 (2021).","journal-title":"Nat. Commun."},{"key":"1274_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2024.101848","volume":"75","author":"A Caicedo","year":"2024","unstructured":"Caicedo, A. et al. Decoding the nature and complexity of extracellular mtDNA: types and implications for health and disease. Mitochondrion 75, 101848 (2024).","journal-title":"Mitochondrion"},{"key":"1274_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00011-026-02231-8","volume":"75","author":"X Wen","year":"2026","unstructured":"Wen, X., Yang, F., Zhang, L. & Huang, D. Mitochondrial DNA as a driver of inflammation via the cGAS-STING pathway. Inflamm. Res. 75, 77 (2026).","journal-title":"Inflamm. Res."},{"key":"1274_CR51","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00109-020-01967-y","volume":"98","author":"A Maresca","year":"2020","unstructured":"Maresca, A. et al. Expanding and validating the biomarkers for mitochondrial diseases. J. Mol. Med. 98, 1467\u20131478 (2020).","journal-title":"J. Mol. Med."},{"key":"1274_CR52","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/clinchem\/hvab091","volume":"67","author":"S Trifunov","year":"2021","unstructured":"Trifunov, S. et al. Circulating cell-free mitochondrial DNA in cerebrospinal fluid as a biomarker for mitochondrial diseases. Clin. Chem. 67, 1113\u20131121 (2021).","journal-title":"Clin. Chem."},{"key":"1274_CR53","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1016\/S0140-6736(18)30727-X","volume":"391","author":"J Rahman","year":"2018","unstructured":"Rahman, J. & Rahman, S. Mitochondrial medicine in the omics era. Lancet 391, 2560\u20132574 (2018).","journal-title":"Lancet"},{"key":"1274_CR54","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.3390\/ijms25094855","volume":"25","author":"J Gervasoni","year":"2024","unstructured":"Gervasoni, J. et al. Mitochondrial biomarkers in the omics era: a clinical-pathophysiological perspective. Int. J. Mol. Sci. 25, 4855 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1274_CR55","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.mito.2017.05.012","volume":"35","author":"K Esterhuizen","year":"2017","unstructured":"Esterhuizen, K., van der Westhuizen, F. H. & Louw, R. Metabolomics of mitochondrial disease. Mitochondrion 35, 97\u2013110 (2017).","journal-title":"Mitochondrion"},{"key":"1274_CR56","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809091","volume":"10","author":"J Buzkova","year":"2018","unstructured":"Buzkova, J. et al. Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers. EMBO Mol. Med. 10, e9091 (2018).","journal-title":"EMBO Mol. Med."},{"key":"1274_CR57","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.celrep.2015.09.054","volume":"13","author":"J Thompson Legault","year":"2015","unstructured":"Thompson Legault, J. et al. A metabolic signature of mitochondrial dysfunction revealed through a monogenic form of Leigh syndrome. Cell Rep. 13, 981\u2013989 (2015).","journal-title":"Cell Rep."},{"key":"1274_CR58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11306-020-01769-w","volume":"17","author":"K Esterhuizen","year":"2021","unstructured":"Esterhuizen, K. et al. One mutation, three phenotypes: novel metabolic insights on MELAS, MIDD and myopathy caused by the m.3243A>G mutation. Metabolomics 17, 10 (2021).","journal-title":"Metabolomics"},{"key":"1274_CR59","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/jdi.14334","volume":"16","author":"B Cao","year":"2025","unstructured":"Cao, B., Lu, H., Liu, P., Zhang, Y. & Wang, C. Serum metabolomics signature of maternally inherited diabetes and deafness by gas chromatography\u2013time of flight mass spectrometry. J. Diabetes Investig. 16, 146\u2013153 (2025).","journal-title":"J. Diabetes Investig."},{"key":"1274_CR60","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3390\/genes11121522","volume":"11","author":"J Gervasoni","year":"2020","unstructured":"Gervasoni, J. et al. Fourier-transform infrared spectroscopy of skeletal muscle tissue: expanding biomarkers in primary mitochondrial myopathies. Genes 11, 1522 (2020).","journal-title":"Genes"},{"key":"1274_CR61","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/ki.2014.297","volume":"87","author":"AM Hall","year":"2015","unstructured":"Hall, A. M. et al. The urinary proteome and metabonome differ from normal in adults with mitochondrial disease. Kidney Int. 87, 610\u2013622 (2015).","journal-title":"Kidney Int."},{"key":"1274_CR62","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.178645","volume":"9","author":"SP Correia","year":"2024","unstructured":"Correia, S. P. et al. Quantitative proteomics of patient fibroblasts reveal biomarkers and diagnostic signatures of mitochondrial disease. JCI Insight 9, e178645 (2024).","journal-title":"JCI Insight"},{"key":"1274_CR63","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ymgme.2013.07.011","volume":"110","author":"C Clarke","year":"2013","unstructured":"Clarke, C. et al. Mitochondrial respiratory chain disease discrimination by retrospective cohort analysis of blood metabolites. Mol. Genet. Metab. 110, 145\u2013152 (2013).","journal-title":"Mol. Genet. Metab."},{"key":"1274_CR64","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.mito.2018.02.003","volume":"45","author":"K Esterhuizen","year":"2019","unstructured":"Esterhuizen, K. et al. A urinary biosignature for mitochondrial myopathy, encephalopathy, lactic acidosis and stroke like episodes (MELAS). Mitochondrion 45, 38\u201345 (2019).","journal-title":"Mitochondrion"},{"key":"1274_CR65","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00234-025-03805-9","volume":"68","author":"P Gaur","year":"2026","unstructured":"Gaur, P. et al. Imaging patterns of paediatric CNS mitochondrial disorders. Neuroradiology 68, 23\u201338 (2026).","journal-title":"Neuroradiology"},{"key":"1274_CR66","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s00330-016-4454-8","volume":"27","author":"RJ Lunsing","year":"2017","unstructured":"Lunsing, R. J., Strating, K., De Koning, T. J. & Sijens, P. E. Diagnostic value of MRS-quantified brain tissue lactate level in identifying children with mitochondrial disorders. Eur. Radiol. 27, 976\u2013984 (2017).","journal-title":"Eur. Radiol."},{"key":"1274_CR67","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jcma.2011.05.006","volume":"74","author":"C-S Chi","year":"2011","unstructured":"Chi, C.-S. et al. Lactate peak on brain MRS in children with syndromic mitochondrial diseases. J. Chin. Med. Assoc. 74, 305\u2013309 (2011).","journal-title":"J. Chin. Med. Assoc."},{"key":"1274_CR68","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/RMR.0000000000000173","volume":"27","author":"CAPF Alves","year":"2018","unstructured":"Alves, C. A. P. F. et al. Neuroimaging of mitochondrial cytopathies. Top. Magn. Reson. Imaging 27, 219\u2013240 (2018).","journal-title":"Top. Magn. Reson. Imaging"},{"key":"1274_CR69","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209728","volume":"103","author":"O Fortin","year":"2024","unstructured":"Fortin, O. et al. Fetal brain MRI abnormalities in pyruvate dehydrogenase complex deficiency. Neurology 103, e209728 (2024).","journal-title":"Neurology"},{"key":"1274_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00324","volume":"21","author":"CAPF Alves","year":"2024","unstructured":"Alves, C. A. P. F. & Whitehead, M. T. Advancing the neuroimaging diagnosis and understanding of mitochondrial disorders. Neurotherapeutics 21, e00324 (2024).","journal-title":"Neurotherapeutics"},{"key":"1274_CR71","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1007\/s00234-025-03689-9","volume":"67","author":"T Sobeh","year":"2025","unstructured":"Sobeh, T. et al. Neuroimaging characteristics of single large-scale mitochondrial DNA deletion syndromes. Neuroradiology 67, 3061\u20133069 (2025).","journal-title":"Neuroradiology"},{"key":"1274_CR72","doi-asserted-by":"publisher","first-page":"1028762","DOI":"10.3389\/fnins.2022.1028762","volume":"16","author":"H Zheng","year":"2023","unstructured":"Zheng, H. et al. Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes with an MT-TL1 m.3243A>G point mutation: neuroradiological features and their implications for underlying pathogenesis. Front. Neurosci. 16, 1028762 (2023).","journal-title":"Front. Neurosci."},{"key":"1274_CR73","first-page":"1958","volume":"24","author":"MC Bianchi","year":"2003","unstructured":"Bianchi, M. C. et al. Proton MR spectroscopy of mitochondrial diseases: analysis of brain metabolic abnormalities and their possible diagnostic relevance. AJNR Am. J. Neuroradiol. 24, 1958\u20131966 (2003).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"1274_CR74","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.mito.2021.06.012","volume":"59","author":"R Wang","year":"2021","unstructured":"Wang, R. et al. Metabolic abnormality in acute stroke-like lesion and its relationship with focal cerebral blood flow in patients with MELAS: evidence from proton MR spectroscopy and arterial spin labeling. Mitochondrion 59, 276\u2013282 (2021).","journal-title":"Mitochondrion"},{"key":"1274_CR75","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3174\/ajnr.A2395","volume":"32","author":"Z Liu","year":"2011","unstructured":"Liu, Z. et al. Apparent diffusion coefficients of metabolites in patients with MELAS using diffusion-weighted MR spectroscopy. Am. J. Neuroradiol. 32, 898\u2013902 (2011).","journal-title":"Am. J. Neuroradiol."},{"key":"1274_CR76","doi-asserted-by":"publisher","first-page":"140","DOI":"10.26815\/acn.2021.00381","volume":"29","author":"H Lee","year":"2021","unstructured":"Lee, H., Shin, J. H., Na, J.-H. & Lee, Y.-M. Clinical value of magnetic resonance spectroscopy in the initial evaluation of patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. Ann. Child Neurol. 29, 140\u2013144 (2021).","journal-title":"Ann. Child Neurol."},{"key":"1274_CR77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3348\/kjr.2011.12.1.15","volume":"12","author":"JH Kim","year":"2011","unstructured":"Kim, J. H. et al. Diffusion and perfusion characteristics of MELAS (Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-Like Episode) in thirteen patients. Korean J. Radiol. 12, 15 (2011).","journal-title":"Korean J. Radiol."},{"key":"1274_CR78","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3390\/genes12101643","volume":"12","author":"C Pizzamiglio","year":"2021","unstructured":"Pizzamiglio, C. et al. Mitochondrial strokes: diagnostic challenges and chameleons. Genes 12, 1643 (2021).","journal-title":"Genes"},{"key":"1274_CR79","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1212\/WNL.0000000000000169","volume":"82","author":"N Weiduschat","year":"2014","unstructured":"Weiduschat, N. et al. Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers. Neurology 82, 798\u2013805 (2014).","journal-title":"Neurology"},{"key":"1274_CR80","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/jcbfm.1993.61","volume":"13","author":"B Barbiroli","year":"1993","unstructured":"Barbiroli, B. et al. Defective brain energy metabolism shown by in vivo 31P MR spectroscopy in 28 patients with mitochondrial cytopathies. J. Cereb. Blood Flow Metab. 13, 469\u2013474 (1993).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"1274_CR81","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.1093\/brain\/awp259","volume":"132","author":"MM Lindroos","year":"2009","unstructured":"Lindroos, M. M. et al. Cerebral oxygen and glucose metabolism in patients with mitochondrial m.3243A>G mutation. Brain. 132, 3274\u20133284 (2009).","journal-title":"Brain."},{"key":"1274_CR82","doi-asserted-by":"crossref","first-page":"e2761","DOI":"10.1212\/WNL.0000000000012033","volume":"96","author":"J van den Ameele","year":"2021","unstructured":"van den Ameele, J. et al. [11C]PK11195-PET brain imaging of the mitochondrial translocator protein in mitochondrial disease. Neurology 96, e2761\u2013e2773 (2021).","journal-title":"Neurology"},{"key":"1274_CR83","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s00330-015-3801-5","volume":"26","author":"RDS Pitceathly","year":"2016","unstructured":"Pitceathly, R. D. S. et al. Extra-ocular muscle MRI in genetically-defined mitochondrial disease. Eur. Radiol. 26, 130\u2013137 (2016).","journal-title":"Eur. Radiol."},{"key":"1274_CR84","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s00415-003-0206-1","volume":"250","author":"DB Olsen","year":"2003","unstructured":"Olsen, D. B. et al. Muscle structural changes in mitochondrial myopathy relate to genotype. J. Neurol. 250, 1328\u20131334 (2003).","journal-title":"J. Neurol."},{"key":"1274_CR85","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.nmd.2018.02.008","volume":"28","author":"G Hedermann","year":"2018","unstructured":"Hedermann, G. et al. Progressive fat replacement of muscle contributes to the disease mechanism of patients with single, large-scale deletions of mitochondrial DNA. Neuromuscul. Disord. 28, 408\u2013413 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"1274_CR86","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.mito.2018.07.001","volume":"46","author":"NS Poulsen","year":"2019","unstructured":"Poulsen, N. S., Dahlqvist, J. R., Hedermann, G., L\u00f8kken, N. & Vissing, J. Muscle contractility of leg muscles in patients with mitochondrial myopathies. Mitochondrion 46, 221\u2013227 (2019).","journal-title":"Mitochondrion"},{"key":"1274_CR87","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00415-006-0229-5","volume":"254","author":"TD Jeppesen","year":"2007","unstructured":"Jeppesen, T. D., Quistorff, B., Wibrand, F. & Vissing, J. 31P-MRS of skeletal muscle is not a sensitive diagnostic test for mitochondrial myopathy. J. Neurol. 254, 29\u201337 (2007).","journal-title":"J. Neurol."},{"key":"1274_CR88","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/jmri.21620","volume":"29","author":"SGC Van Elderen","year":"2009","unstructured":"Van Elderen, S. G. C. et al. Phosphorus-31 magnetic resonance spectroscopy of skeletal muscle in maternally inherited diabetes and deafness A3243G mitochondrial mutation carriers. J. Magn. Reson. Imaging 29, 127\u2013131 (2009).","journal-title":"J. Magn. Reson. Imaging"},{"key":"1274_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97928-7","volume":"11","author":"T Singh","year":"2021","unstructured":"Singh, T. et al. Neuronal mitochondrial dysfunction in sporadic amyotrophic lateral sclerosis is developmentally regulated. Sci. Rep. 11, 18916 (2021).","journal-title":"Sci. Rep."},{"key":"1274_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59679-1","volume":"16","author":"C Schweingruber","year":"2025","unstructured":"Schweingruber, C. et al. Single-cell RNA-sequencing reveals early mitochondrial dysfunction unique to motor neurons shared across FUS- and TARDBP-ALS. Nat. Commun. 16, 4633 (2025).","journal-title":"Nat. Commun."},{"key":"1274_CR91","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1146\/annurev-biochem-032620-104401","volume":"92","author":"LE Newman","year":"2023","unstructured":"Newman, L. E. & Shadel, G. S. Mitochondrial DNA release in innate immune signaling. Annu. Rev. Biochem. 92, 299\u2013332 (2023).","journal-title":"Annu. Rev. Biochem."},{"key":"1274_CR92","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00415-015-7737-0","volume":"262","author":"JK Ehinger","year":"2015","unstructured":"Ehinger, J. K., Morota, S., Hansson, M. J., Paul, G. & Elm\u00e9r, E. Mitochondrial dysfunction in blood cells from amyotrophic lateral sclerosis patients. J. Neurol. 262, 1493\u20131503 (2015).","journal-title":"J. Neurol."},{"key":"1274_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-00933-2","volume":"12","author":"A Stoccoro","year":"2020","unstructured":"Stoccoro, A. et al. Reduced mitochondrial D-loop methylation levels in sporadic amyotrophic lateral sclerosis. Clin. Epigenetics 12, 137 (2020).","journal-title":"Clin. Epigenetics"},{"key":"1274_CR94","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.2217\/epi-2018-0072","volume":"10","author":"A Stoccoro","year":"2018","unstructured":"Stoccoro, A. et al. Mitochondrial DNA copy number and D-loop region methylation in carriers of amyotrophic lateral sclerosis gene mutations. Epigenomics 10, 1431\u20131443 (2018).","journal-title":"Epigenomics"},{"key":"1274_CR95","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2217\/epi-2023-0265","volume":"16","author":"A Stoccoro","year":"2024","unstructured":"Stoccoro, A. et al. Mitochondrial D-loop methylation levels inversely correlate with disease duration in amyotrophic lateral sclerosis. Epigenomics 16, 203\u2013214 (2024).","journal-title":"Epigenomics"},{"key":"1274_CR96","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40246-023-00516-1","volume":"17","author":"SJ Brockmann","year":"2023","unstructured":"Brockmann, S. J. et al. Mitochondrial genome study in blood of maternally inherited ALS cases. Hum. Genom. 17, 70 (2023).","journal-title":"Hum. Genom."},{"key":"1274_CR97","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16493","volume":"31","author":"J Li","year":"2024","unstructured":"Li, J. et al. Elevated serum circulating cell-free mitochondrial DNA in amyotrophic lateral sclerosis. Eur. J. Neurol. 31, e16493 (2024).","journal-title":"Eur. J. Neurol."},{"key":"1274_CR98","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/cells14181433","volume":"14","author":"G Zanini","year":"2025","unstructured":"Zanini, G. et al. Circulating serum cell-free mitochondrial DNA in amyotrophic lateral sclerosis. Cells 14, 1433 (2025).","journal-title":"Cells"},{"key":"1274_CR99","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1093\/brain\/awaa340","volume":"143","author":"M Sassani","year":"2020","unstructured":"Sassani, M. et al. Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic lateral sclerosis. Brain 143, 3603\u20133618 (2020).","journal-title":"Brain"},{"key":"1274_CR100","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3109\/21678421.2015.1053490","volume":"16","author":"E Gray","year":"2015","unstructured":"Gray, E. et al. The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 16, 456\u2013463 (2015).","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"1274_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013223","volume":"5","author":"H Blasco","year":"2010","unstructured":"Blasco, H. et al. 1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS ONE 5, e13223 (2010).","journal-title":"PLoS ONE"},{"key":"1274_CR102","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s11011-025-01616-8","volume":"40","author":"P Gautam","year":"2025","unstructured":"Gautam, P., Yadav, R., Vishwakarma, R. K., Pathak, A. & Singh, C. Metabolic dysregulation in amyotrophic lateral sclerosis: insights from 1H NMR-based metabolomics in a tertiary care center in India. Metab. Brain Dis. 40, 196 (2025).","journal-title":"Metab. Brain Dis."},{"key":"1274_CR103","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","volume":"20","author":"[No authors listed].","year":"2024","unstructured":"[No authors listed]. 2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 20, 3708\u20133821 (2024).","journal-title":"Alzheimers Dement."},{"key":"1274_CR104","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3233\/JAD-240092","volume":"101","author":"W Wei","year":"2024","unstructured":"Wei, W., Jiang, Y., Hu, G., He, Y. & Chen, H. Recent advances of mitochondrial alterations in alzheimer\u2019s disease: a perspective of mitochondrial basic events. J. Alzheimers Dis. 101, 379\u2013396 (2024).","journal-title":"J. Alzheimers Dis."},{"key":"1274_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2026.1772036","volume":"17","author":"X Xiao","year":"2026","unstructured":"Xiao, X., Yan, X., Liang, C. & Yang, Y. Metabolic dysfunction and mitochondrial failure in Alzheimer\u2019s disease: integrating pathophysiology, clinical evidence and emerging interventions. Front. Neurol. 17, 1772036 (2026).","journal-title":"Front. Neurol."},{"key":"1274_CR106","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2174\/1570159X19666210517114016","volume":"20","author":"S Bhatia","year":"2022","unstructured":"Bhatia, S. et al. Mitochondrial dysfunction in alzheimer\u2019s disease: opportunities for drug development. Curr. Neuropharmacol. 20, 675\u2013692 (2022).","journal-title":"Curr. Neuropharmacol."},{"key":"1274_CR107","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0197-4580(03)00033-2","volume":"25","author":"SM Cardoso","year":"2004","unstructured":"Cardoso, S. M., Proen\u00e7a, M. T., Santos, S., Santana, I. & Oliveira, C. R. Cytochrome c oxidase is decreased in Alzheimer\u2019s disease platelets. Neurobiol. Aging 25, 105\u2013110 (2004).","journal-title":"Neurobiol. Aging"},{"key":"1274_CR108","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1212\/WNL.44.6.1086","volume":"44","author":"WD Parker","year":"1994","unstructured":"Parker, W. D. et al. Reduced platelet cytochrome c oxidase activity in Alzheimer\u2019s disease. Neurology 44, 1086\u20131090 (1994).","journal-title":"Neurology"},{"key":"1274_CR109","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3233\/JAD-170077","volume":"59","author":"HM Wilkins","year":"2017","unstructured":"Wilkins, H. M. et al. A mitochondrial biomarker-based study of s-equol in alzheimer\u2019s disease subjects: results of a single-arm, pilot trial. J. Alzheimers Dis. JAD. 59, 291\u2013300 (2017).","journal-title":"J. Alzheimers Dis. JAD."},{"key":"1274_CR110","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1136\/jnnp-2014-308577","volume":"86","author":"C Liguori","year":"2015","unstructured":"Liguori, C. et al. CSF lactate levels, \u03c4 proteins, cognitive decline: a dynamic relationship in Alzheimer\u2019s disease. J. Neurol. Neurosurg. Psychiatry 86, 655\u2013659 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1274_CR111","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1159\/000022031","volume":"44","author":"N Redjems-Bennani","year":"1998","unstructured":"Redjems-Bennani, N. et al. Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from alzheimer patients. Gerontology 44, 300\u2013304 (1998).","journal-title":"Gerontology"},{"key":"1274_CR112","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.neurobiolaging.2021.05.011","volume":"105","author":"CG Bonomi","year":"2021","unstructured":"Bonomi, C. G. et al. Brain energy metabolism and neurodegeneration: hints from CSF lactate levels in dementias. Neurobiol. Aging 105, 333\u2013339 (2021).","journal-title":"Neurobiol. Aging"},{"key":"1274_CR113","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13195-022-01004-9","volume":"14","author":"PT Zebhauser","year":"2022","unstructured":"Zebhauser, P. T. et al. Cerebrospinal fluid lactate levels along the Alzheimer\u2019s disease continuum and associations with blood-brain barrier integrity, age, cognition, and biomarkers. Alzheimers Res. Ther. 14, 61 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"1274_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.700371","volume":"12","author":"P-F Wu","year":"2021","unstructured":"Wu, P.-F. et al. Growth differentiation factor 15 is associated with Alzheimer\u2019s disease risk. Front. Genet. 12, 700371 (2021).","journal-title":"Front. Genet."},{"key":"1274_CR115","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251314773","volume":"18","author":"D Plantone","year":"2025","unstructured":"Plantone, D. et al. CSF IL-6, GDF-15, GFAP and NfL levels in early Alzheimer disease: a pilot study. Ther. Adv. Neurol. Disord. 18, 17562864251314773 (2025).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"1274_CR116","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/ana.23955","volume":"74","author":"P Podlesniy","year":"2013","unstructured":"Podlesniy, P. et al. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Ann. Neurol. 74, 655\u2013668 (2013).","journal-title":"Ann. Neurol."},{"key":"1274_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04634-x","volume":"23","author":"J Huang","year":"2023","unstructured":"Huang, J. et al. Immunological evaluation of patients with Alzheimer\u2019s disease based on mitogen-stimulated cytokine productions and mitochondrial DNA indicators. BMC Psychiatry 23, 145 (2023).","journal-title":"BMC Psychiatry"},{"key":"1274_CR118","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.3390\/ijms21176298","volume":"21","author":"P Podlesniy","year":"2020","unstructured":"Podlesniy, P. et al. Cerebrospinal fluid mitochondrial DNA in rapid and slow progressive forms of alzheimer\u2019s disease. Int. J. Mol. Sci. 21, 6298 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1274_CR119","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jalz.2015.12.011","volume":"12","author":"P Podlesniy","year":"2016","unstructured":"Podlesniy, P. et al. Mitochondrial DNA differentiates alzheimer\u2019s disease from creutzfeldt-jakob disease. Alzheimers Dement. 12, 546\u2013555 (2016).","journal-title":"Alzheimers Dement."},{"key":"1274_CR120","doi-asserted-by":"publisher","first-page":"192.e1","DOI":"10.1016\/j.neurobiolaging.2016.12.009","volume":"53","author":"L Cervera-Carles","year":"2017","unstructured":"Cervera-Carles, L. et al. Cerebrospinal fluid mitochondrial DNA in the Alzheimer\u2019s disease continuum. Neurobiol. Aging 53, 192.e1\u2013192.e4 (2017).","journal-title":"Neurobiol. Aging"},{"key":"1274_CR121","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","volume":"30","author":"J Fortea","year":"2024","unstructured":"Fortea, J. et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer\u2019s disease. Nat. Med. 30, 1284\u20131291 (2024).","journal-title":"Nat. Med."},{"key":"1274_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2025.102032","volume":"83","author":"P Qin","year":"2025","unstructured":"Qin, P. et al. Mitochondrial DNA copy number and Alzheimer\u2019s disease and Parkinson disease. Mitochondrion 83, 102032 (2025).","journal-title":"Mitochondrion"},{"key":"1274_CR123","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41380-024-02670-x","volume":"30","author":"H Stocker","year":"2025","unstructured":"Stocker, H. et al. Mitochondrial DNA abundance in blood is associated with Alzheimer\u2019s disease- and dementia-risk. Mol. Psychiatry 30, 131\u2013139 (2025).","journal-title":"Mol. Psychiatry"},{"key":"1274_CR124","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1101\/gr.269381.120","volume":"31","author":"SY Yang","year":"2021","unstructured":"Yang, S. Y. et al. Blood-derived mitochondrial DNA copy number is associated with gene expression across multiple tissues and is predictive for incident neurodegenerative disease. Genom. Res. 31, 349\u2013358 (2021).","journal-title":"Genom. Res."},{"key":"1274_CR125","doi-asserted-by":"publisher","first-page":"e1930","DOI":"10.1212\/WNL.0000000000207157","volume":"100","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Association of mitochondrial DNA copy number with brain MRI markers and cognitive function: a meta-analysis of community-based cohorts. Neurology 100, e1930\u2013e1943 (2023).","journal-title":"Neurology"},{"key":"1274_CR126","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/ene.15246","volume":"29","author":"T Terada","year":"2022","unstructured":"Terada, T. et al. Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer\u2019s disease. Eur. J. Neurol. 29, 1324\u20131334 (2022).","journal-title":"Eur. J. Neurol."},{"key":"1274_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101503","volume":"72","author":"T Song","year":"2021","unstructured":"Song, T. et al. Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer\u2019s disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies. Ageing Res. Rev. 72, 101503 (2021).","journal-title":"Ageing Res. Rev."},{"key":"1274_CR128","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1002\/alz.13388","volume":"19","author":"Q Tian","year":"2023","unstructured":"Tian, Q. et al. Skeletal muscle mitochondrial function predicts cognitive impairment and is associated with biomarkers of Alzheimer\u2019s disease and neurodegeneration. Alzheimers Dement. 19, 4436\u20134445 (2023).","journal-title":"Alzheimers Dement."},{"key":"1274_CR129","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/jnr.24263","volume":"96","author":"M Ripolone","year":"2018","unstructured":"Ripolone, M. et al. Purkinje cell COX deficiency and mtDNA depletion in an animal model of spinocerebellar ataxia type 1. J. Neurosci. Res. 96, 1576\u20131585 (2018).","journal-title":"J. Neurosci. Res."},{"key":"1274_CR130","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3389\/fnins.2020.00707","volume":"14","author":"KJ Robinson","year":"2020","unstructured":"Robinson, K. J., Watchon, M. & Laird, A. S. Aberrant cerebellar circuitry in the spinocerebellar ataxias. Front. Neurosci. 14, 707 (2020).","journal-title":"Front. Neurosci."},{"key":"1274_CR131","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1113\/JP271897","volume":"594","author":"P Meera","year":"2016","unstructured":"Meera, P., Pulst, S. M. & Otis, T. S. Cellular and circuit mechanisms underlying spinocerebellar ataxias. J. Physiol. 594, 4653\u20134660 (2016).","journal-title":"J. Physiol."},{"key":"1274_CR132","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00401-025-02891-6","volume":"149","author":"LA Smith","year":"2025","unstructured":"Smith, L. A. et al. Delineating the mechanisms of cerebellar degeneration in paediatric and adult primary mitochondrial disease. Acta Neuropathol. 149, 53 (2025).","journal-title":"Acta Neuropathol."},{"key":"1274_CR133","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1042\/CS20160072","volume":"130","author":"S Chiang","year":"2016","unstructured":"Chiang, S. et al. Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich\u2019s ataxia. Clin Sci. 130, 853\u2013870 (2016).","journal-title":"Clin Sci."},{"key":"1274_CR134","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(25)00175-9","volume":"24","author":"K Reetz","year":"2025","unstructured":"Reetz, K. et al. Friedreich\u2019s ataxia \u2014 a rare multisystem disease. Lancet Neurol. 24, 614\u2013624 (2025).","journal-title":"Lancet Neurol."},{"key":"1274_CR135","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(10)70183-6","volume":"9","author":"A Durr","year":"2010","unstructured":"Durr, A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 9, 885\u2013894 (2010).","journal-title":"Lancet Neurol."},{"key":"1274_CR136","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cca.2012.09.019","volume":"414","author":"S-L Su","year":"2012","unstructured":"Su, S.-L. et al. FGF21 in ataxia patients with spinocerebellar atrophy and mitochondrial disease. Clin. Chim. Acta 414, 225\u2013227 (2012).","journal-title":"Clin. Chim. Acta"},{"key":"1274_CR137","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1007\/s11033-013-2767-0","volume":"40","author":"MH Salehi","year":"2013","unstructured":"Salehi, M. H. et al. Association of fibroblast growth factor (FGF-21) as a biomarker with primary mitochondrial disorders, but not with secondary mitochondrial disorders (Friedreich ataxia). Mol. Biol. Rep. 40, 6495\u20136499 (2013).","journal-title":"Mol. Biol. Rep."},{"key":"1274_CR138","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/biom10030390","volume":"10","author":"R Nambo-Venegas","year":"2020","unstructured":"Nambo-Venegas, R. et al. Altered plasma acylcarnitines and amino acids profile in spinocerebellar ataxia type 7. Biomolecules 10, 390 (2020).","journal-title":"Biomolecules"},{"key":"1274_CR139","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2007.07.016","volume":"264","author":"C-S Liu","year":"2008","unstructured":"Liu, C.-S. et al. Depletion of mitochondrial DNA in leukocytes of patients with poly-Q diseases. J. Neurol. Sci. 264, 18\u201321 (2008).","journal-title":"J. Neurol. Sci."},{"key":"1274_CR140","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12035-018-1069-x","volume":"56","author":"M Raposo","year":"2019","unstructured":"Raposo, M. et al. Accumulation of mitochondrial DNA common deletion since the preataxic stage of Machado-Joseph disease. Mol. Neurobiol. 56, 119\u2013124 (2019).","journal-title":"Mol. Neurobiol."},{"key":"1274_CR141","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2016.04.016","volume":"365","author":"S Dantham","year":"2016","unstructured":"Dantham, S., Srivastava, A. K., Gulati, S. & Rajeswari, M. R. Plasma circulating cell-free mitochondrial DNA in the assessment of Friedreich\u2019s ataxia. J. Neurol. Sci. 365, 82\u201388 (2016).","journal-title":"J. Neurol. Sci."},{"key":"1274_CR142","doi-asserted-by":"publisher","first-page":"11492","DOI":"10.1073\/pnas.96.20.11492","volume":"96","author":"R Lodi","year":"1999","unstructured":"Lodi, R. et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl Acad. Sci. USA 96, 11492\u201311495 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1274_CR143","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.neubiorev.2019.12.019","volume":"108","author":"J Krahe","year":"2020","unstructured":"Krahe, J., Binkofski, F., Schulz, J. B., Reetz, K. & Romanzetti, S. Neurochemical profiles in hereditary ataxias: a meta-analysis of magnetic resonance spectroscopy studies. Neurosci. Biobehav. Rev. 108, 854\u2013865 (2020).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1274_CR144","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S0960-8966(00)00108-5","volume":"10","author":"M Vorgerd","year":"2000","unstructured":"Vorgerd, M. et al. Mitochondrial impairment of human muscle in Friedreich ataxia in vivo. Neuromuscul. Disord. 10, 430\u2013435 (2000).","journal-title":"Neuromuscul. Disord."},{"key":"1274_CR145","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/ana.1001","volume":"49","author":"R Lodi","year":"2001","unstructured":"Lodi, R. et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich\u2019s ataxia. Ann. Neurol. 49, 590\u2013596 (2001).","journal-title":"Ann. Neurol."},{"key":"1274_CR146","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/archneur.62.4.621","volume":"62","author":"PE Hart","year":"2005","unstructured":"Hart, P. E. et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol. 62, 621 (2005).","journal-title":"Arch. Neurol."},{"key":"1274_CR147","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10493","volume":"14","author":"JA Gonzalez-Chapa","year":"2023","unstructured":"Gonzalez-Chapa, J. A., Mac\u00eado, M. B. & Lood, C. The emerging role of mitochondrial dysfunction in the pathogenesis of idiopathic inflammatory myopathies. Rambam Maimonides Med. J. 14, e0006 (2023).","journal-title":"Rambam Maimonides Med. J."},{"key":"1274_CR148","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.31458","volume":"240","author":"A Thoma","year":"2025","unstructured":"Thoma, A. et al. A combination of major histocompatibility complex (MHC) I overexpression and type I interferon induce mitochondrial dysfunction in human skeletal myoblasts. J. Cell Physiol. 240, e31458 (2025).","journal-title":"J. Cell Physiol."},{"key":"1274_CR149","first-page":"384","volume":"44","author":"F Torri","year":"2026","unstructured":"Torri, F., Ricci, G., Mancuso, M. & Siciliano, G. Mitochondrial abnormalities in idiopathic inflammatory myopathies. Clin. Exp. Rheumatol. 44, 384\u2013389 (2026).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1274_CR150","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40478-026-02243-9","volume":"14","author":"F Kleefeld","year":"2026","unstructured":"Kleefeld, F. et al. Proteomic profiles in inclusion body myositis and polymyositis with mitochondrial pathology. Acta Neuropathol. Commun. 14, 49 (2026).","journal-title":"Acta Neuropathol. Commun."},{"key":"1274_CR151","doi-asserted-by":"publisher","first-page":"e2212","DOI":"10.1212\/WNL.0000000000201103","volume":"99","author":"F Kleefeld","year":"2022","unstructured":"Kleefeld, F. et al. Morphologic and molecular patterns of polymyositis with mitochondrial pathology and inclusion body myositis. Neurology 99, e2212\u2013e2222 (2022).","journal-title":"Neurology"},{"key":"1274_CR152","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1007\/s10072-023-07035-w","volume":"44","author":"A Lauletta","year":"2023","unstructured":"Lauletta, A. et al. Prominent mitochondrial pathology in a case of refractory dermatomyositis: coincidence or concause? Neurol. Sci. 44, 4525\u20134529 (2023).","journal-title":"Neurol. Sci."},{"key":"1274_CR153","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00401-017-1731-9","volume":"134","author":"A Meyer","year":"2017","unstructured":"Meyer, A. et al. IFN-\u03b2-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis. Acta Neuropathol. 134, 655\u2013666 (2017).","journal-title":"Acta Neuropathol."},{"key":"1274_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103522","volume":"158","author":"C Leijding","year":"2026","unstructured":"Leijding, C. et al. Sera from patients with dermatomyositis and antisynthetase syndrome mediate muscle weakness, impair mitochondrial respiration and induce local cytokine production in muscle tissue. J. Autoimmun. 158, 103522 (2026).","journal-title":"J. Autoimmun."},{"key":"1274_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2024.101945","volume":"78","author":"G Mak","year":"2024","unstructured":"Mak, G., Tarnopolsky, M. & Lu, J.-Q. Secondary mitochondrial dysfunction across the spectrum of hereditary and acquired muscle disorders. Mitochondrion 78, 101945 (2024).","journal-title":"Mitochondrion"},{"key":"1274_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.154966","volume":"127","author":"B De Paepe","year":"2020","unstructured":"De Paepe, B., Verhamme, F. & De Bleecker, J. L. The myokine GDF-15 is a potential biomarker for myositis and associates with the protein aggregates of sporadic inclusion body myositis. Cytokine 127, 154966 (2020).","journal-title":"Cytokine"},{"key":"1274_CR157","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/brainsci13101369","volume":"13","author":"B De Paepe","year":"2023","unstructured":"De Paepe, B., Bracke, K. R. & De Bleecker, J. L. Retrospective study shows that serum levels of chemokine CXCL10 and cytokine GDF15 support a diagnosis of sporadic inclusion body myositis and immune-mediated necrotizing myopathy. Brain Sci. 13, 1369 (2023).","journal-title":"Brain Sci."},{"key":"1274_CR158","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/1744666X.2022.2021879","volume":"18","author":"B De Paepe","year":"2022","unstructured":"De Paepe, B. Growth differentiation factor-15 as an emerging biomarker for identifying myositis. Expert Rev. Clin. Immunol. 18, 115\u2013123 (2022).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"1274_CR159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231064","volume":"15","author":"Y Oikawa","year":"2020","unstructured":"Oikawa, Y. et al. Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5. PLoS ONE 15, e0231064 (2020).","journal-title":"PLoS ONE"},{"key":"1274_CR160","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/rheumatology\/kead654","volume":"64","author":"B Duvvuri","year":"2023","unstructured":"Duvvuri, B. et al. The emerging role of growth differentiation factor 15 as a potential disease biomarker in juvenile dermatomyositis. Rheumatology 64, 805\u2013809 (2023).","journal-title":"Rheumatology"},{"key":"1274_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2024.103058","volume":"55","author":"Q Wu","year":"2024","unstructured":"Wu, Q. et al. Activity prediction modeling based on a combination of growth differentiation factor 15 and serum biomarker levels in dermatomyositis and polymyositis. Arch. Med. Res. 55, 103058 (2024).","journal-title":"Arch. Med. Res."},{"key":"1274_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09943-x","volume":"12","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y. et al. The SNPs of mitochondrial DNA displacement loop region and mitochondrial DNA copy number associated with risk of polymyositis and dermatomyositis. Sci. Rep. 12, 5903 (2022).","journal-title":"Sci. Rep."},{"key":"1274_CR163","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1093\/nar\/gkw382","volume":"44","author":"KA Rygiel","year":"2016","unstructured":"Rygiel, K. A. et al. Complex mitochondrial DNA rearrangements in individual cells from patients with sporadic inclusion body myositis. Nucleic Acids Res. 44, 5313\u20135329 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1274_CR164","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1212\/01.wnl.0000192127.63013.8d","volume":"66","author":"A Oldfors","year":"2006","unstructured":"Oldfors, A. et al. Mitochondrial abnormalities in inclusion-body myositis. Neurology 66, S49\u2013S55 (2006).","journal-title":"Neurology"},{"key":"1274_CR165","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.nmd.2019.02.001","volume":"29","author":"PS Bhatt","year":"2019","unstructured":"Bhatt, P. S. et al. Mitochondrial DNA depletion in sporadic inclusion body myositis. Neuromuscul. Disord. 29, 242\u2013246 (2019).","journal-title":"Neuromuscul. Disord."},{"key":"1274_CR166","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1093\/brain\/awaf118","volume":"148","author":"F Kleefeld","year":"2025","unstructured":"Kleefeld, F. et al. Mitochondrial damage is associated with an early immune response in inclusion body myositis. Brain J. Neurol. 148, 3199\u20133214 (2025).","journal-title":"Brain J. Neurol."},{"key":"1274_CR167","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1007\/s00415-022-11146-3","volume":"269","author":"X Zhao","year":"2022","unstructured":"Zhao, X. et al. Circulating cell-free mtDNA release is associated with the activation of cGAS-STING pathway and inflammation in mitochondrial diseases. J. Neurol. 269, 4985\u20134996 (2022).","journal-title":"J. Neurol."},{"key":"1274_CR168","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","volume":"14","author":"DH Mahad","year":"2015","unstructured":"Mahad, D. H., Trapp, B. D. & Lassmann, H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 14, 183\u2013193 (2015).","journal-title":"Lancet Neurol."},{"key":"1274_CR169","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ana.26913","volume":"96","author":"M Calabrese","year":"2024","unstructured":"Calabrese, M. et al. Determinants and biomarkers of progression independent of relapses in multiple sclerosis. Ann. Neurol. 96, 1\u201320 (2024).","journal-title":"Ann. Neurol."},{"key":"1274_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.107159","volume":"217","author":"T Xie","year":"2025","unstructured":"Xie, T. et al. Bidirectional relationship between mitochondrial dysfunction and dysregulated lipid metabolism in Multiple Sclerosis: potential mechanisms and therapeutic implications. Neurobiol. Dis. 217, 107159 (2025).","journal-title":"Neurobiol. Dis."},{"key":"1274_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578268","volume":"387","author":"M-E Baeva","year":"2024","unstructured":"Baeva, M.-E., Tottenham, I., Koch, M. & Camara-Lemarroy, C. Biomarkers of disability worsening in inactive primary progressive multiple sclerosis. J. Neuroimmunol. 387, 578268 (2024).","journal-title":"J. Neuroimmunol."},{"key":"1274_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102434","volume":"45","author":"P Kosa","year":"2020","unstructured":"Kosa, P. et al. Idebenone does not inhibit disability progression in primary progressive MS. Mult. Scler. Relat. Disord. 45, 102434 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1274_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116429","volume":"405","author":"S Nohara","year":"2019","unstructured":"Nohara, S. et al. GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis. J. Neurol. Sci. 405, 116429 (2019).","journal-title":"J. Neurol. Sci."},{"key":"1274_CR174","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000675","volume":"7","author":"A Amstad","year":"2020","unstructured":"Amstad, A. et al. Growth differentiation factor 15 is increased in stable MS. Neurol. Neuroimmunol. Neuroinflamm. 7, e675 (2020).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1274_CR175","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.bbadis.2014.04.005","volume":"1842","author":"AM Amorini","year":"2014","unstructured":"Amorini, A. M. et al. Serum lactate as a novel potential biomarker in multiple sclerosis. Biochim. Biophys. Acta 1842, 1137\u20131143 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"1274_CR176","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000595","volume":"2","author":"NW Lutz","year":"2007","unstructured":"Lutz, N. W. et al. Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS ONE 2, e595 (2007).","journal-title":"PLoS ONE"},{"key":"1274_CR177","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12974-016-0502-1","volume":"13","author":"M Albanese","year":"2016","unstructured":"Albanese, M. et al. Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression. J. Neuroinflamm. 13, 36 (2016).","journal-title":"J. Neuroinflamm."},{"key":"1274_CR178","first-page":"171","volume":"27","author":"MA Fonalledas Perell\u00f3","year":"2008","unstructured":"Fonalledas Perell\u00f3, M. A., Politi, J. V., Dallo Lizarraga, M. A. & Cardona, R. S. The cerebrospinal fluid lactate is decreased in early stages of multiple sclerosis. P. R. Health Sci. J. 27, 171\u2013174 (2008).","journal-title":"P. R. Health Sci. J."},{"key":"1274_CR179","doi-asserted-by":"publisher","first-page":"7520","DOI":"10.1007\/s12035-016-0257-9","volume":"54","author":"G Lazzarino","year":"2017","unstructured":"Lazzarino, G. et al. Serum compounds of energy metabolism impairment are related to disability, disease course and neuroimaging in multiple sclerosis. Mol. Neurobiol. 54, 7520\u20137533 (2017).","journal-title":"Mol. Neurobiol."},{"key":"1274_CR180","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1177\/1352458517699874","volume":"24","author":"CE Leurs","year":"2018","unstructured":"Leurs, C. E. et al. Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment. Mult. Scler. J. 24, 472\u2013480 (2018).","journal-title":"Mult. Scler. J."},{"key":"1274_CR181","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.mito.2016.12.003","volume":"34","author":"KN Varhaug","year":"2017","unstructured":"Varhaug, K. N. et al. Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis. Mitochondrion 34, 32\u201335 (2017).","journal-title":"Mitochondrion"},{"key":"1274_CR182","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1177\/1352458518786055","volume":"25","author":"N Fissolo","year":"2019","unstructured":"Fissolo, N. et al. Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. Mult. Scler. J. 25, 1535\u20131538 (2019).","journal-title":"Mult. Scler. J."},{"key":"1274_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105482","volume":"84","author":"I Pavlovic","year":"2024","unstructured":"Pavlovic, I. et al. Cerebrospinal fluid mtDNA concentrations are increased in multiple sclerosis and were normalized after intervention with autologous hematopoietic stem cell transplantation. Mult. Scler. Relat. Disord. 84, 105482 (2024).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1274_CR184","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s12017-019-08588-w","volume":"22","author":"G Al-Kafaji","year":"2020","unstructured":"Al-Kafaji, G. et al. Mitochondrial DNA copy number in peripheral blood as a potential non-invasive biomarker for multiple sclerosis. NeuroMolecular Med. 22, 304\u2013313 (2020).","journal-title":"NeuroMolecular Med."},{"key":"1274_CR185","doi-asserted-by":"publisher","first-page":"121","DOI":"10.55133\/eji.300413","volume":"30","author":"RM Sedky","year":"2023","unstructured":"Sedky, R. M. et al. Mitochondrial DNA copy number as a biomarker of multiple sclerosis. Egypt. J. Immunol. 30, 121\u2013133 (2023).","journal-title":"Egypt. J. Immunol."},{"key":"1274_CR186","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3390\/ijms24020916","volume":"24","author":"GDC L\u00f3pez-Armas","year":"2023","unstructured":"L\u00f3pez-Armas, G. D. C. et al. Leukocyte telomere length predicts severe disability in relapsing-remitting multiple sclerosis and correlates with mitochondrial DNA copy number. Int. J. Mol. Sci. 24, 916 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1274_CR187","doi-asserted-by":"publisher","first-page":"11643","DOI":"10.1007\/s12035-025-04980-9","volume":"62","author":"H Sabaie","year":"2025","unstructured":"Sabaie, H. et al. Mitochondrial DNA copy number as a hidden player in the progression of multiple sclerosis: a bidirectional two-sample Mendelian randomization study. Mol. Neurobiol. 62, 11643\u201311653 (2025).","journal-title":"Mol. Neurobiol."},{"key":"1274_CR188","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1177\/1352458512452924","volume":"18","author":"J Van Horssen","year":"2012","unstructured":"Van Horssen, J., Witte, M. & Ciccarelli, O. The role of mitochondria in axonal degeneration and tissue repair in MS. Mult. Scler. J. 18, 1058\u20131067 (2012).","journal-title":"Mult. Scler. J."},{"key":"1274_CR189","doi-asserted-by":"publisher","first-page":"12631","DOI":"10.3390\/ijms241612631","volume":"24","author":"D Pukoli","year":"2023","unstructured":"Pukoli, D. & V\u00e9csei, L. Smouldering lesion in MS: microglia, lymphocytes and pathobiochemical mechanisms. Int. J. Mol. Sci. 24, 12631 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1274_CR190","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/s41556-024-01513-9","volume":"26","author":"DP Narendra","year":"2024","unstructured":"Narendra, D. P. & Youle, R. J. The role of PINK1-parkin in mitochondrial quality control. Nat. Cell Biol. 26, 1639\u20131651 (2024).","journal-title":"Nat. Cell Biol."},{"key":"1274_CR191","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41583-024-00812-2","volume":"25","author":"R Coukos","year":"2024","unstructured":"Coukos, R. & Krainc, D. Key genes and convergent pathogenic mechanisms in Parkinson disease. Nat. Rev. Neurosci. 25, 393\u2013413 (2024).","journal-title":"Nat. Rev. Neurosci."},{"key":"1274_CR192","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2174\/1871527322666230330122444","volume":"23","author":"M Ciocca","year":"2024","unstructured":"Ciocca, M. & Pizzamiglio, C. Clinical benefits of therapeutic interventions targeting mitochondria in Parkinson\u2019s disease patients. CNS Neurol. Disord. Drug Targets 23, 554\u2013561 (2024).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"1274_CR193","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s11910-023-01260-8","volume":"23","author":"A Legati","year":"2023","unstructured":"Legati, A. & Ghezzi, D. Parkinson\u2019s disease, parkinsonisms, and mitochondria: the role of nuclear and mitochondrial DNA. Curr. Neurol. Neurosci. Rep. 23, 131\u2013147 (2023).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"1274_CR194","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149349","volume":"11","author":"W Maetzler","year":"2016","unstructured":"Maetzler, W. et al. GDF15\/MIC1 and MMP9 cerebrospinal fluid levels in Parkinson\u2019s disease and Lewy body dementia. PLoS ONE 11, e0149349 (2016).","journal-title":"PLoS ONE"},{"key":"1274_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116616","volume":"409","author":"N Miyaue","year":"2020","unstructured":"Miyaue, N., Yabe, H. & Nagai, M. Serum growth differentiation factor 15, but not lactate, is elevated in patients with Parkinson\u2019s disease. J. Neurol. Sci. 409, 116616 (2020).","journal-title":"J. Neurol. Sci."},{"key":"1274_CR196","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000477349","volume":"17","author":"X Yao","year":"2017","unstructured":"Yao, X. et al. Serum growth differentiation factor 15 in Parkinson disease. Neurodegener. Dis. 17, 251\u2013260 (2017).","journal-title":"Neurodegener. Dis."},{"key":"1274_CR197","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/01616412.2025.2480331","volume":"47","author":"J Wang","year":"2025","unstructured":"Wang, J., Geng, T., Yao, X. & Liu, Y. The relationship between serum GDF15 levels and non-motor symptoms in Parkinson\u2019s disease. Neurol. Res. 47, 373\u2013382 (2025).","journal-title":"Neurol. Res."},{"key":"1274_CR198","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214131","volume":"105","author":"E Benarroch","year":"2025","unstructured":"Benarroch, E. What is the potential relevance of growth and differentiation factor-15 in neurologic disease? Neurology 105, e214131 (2025).","journal-title":"Neurology"},{"key":"1274_CR199","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1212\/CPJ.0000000000000702","volume":"10","author":"RL Davis","year":"2020","unstructured":"Davis, R. L. et al. Serum FGF-21, GDF-15, and blood mtDNA copy number are not biomarkers of Parkinson disease. Neurol. Clin. Pract. 10, 40\u201346 (2020).","journal-title":"Neurol. Clin. Pract."},{"key":"1274_CR200","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3390\/neurolint15030066","volume":"15","author":"N Miyaue","year":"2023","unstructured":"Miyaue, N., Yabe, H. & Nagai, M. Serum GDF-15 levels in patients with Parkinson\u2019s disease, progressive supranuclear palsy, and multiple system atrophy. Neurol. Int. 15, 1044\u20131051 (2023).","journal-title":"Neurol. Int."},{"key":"1274_CR201","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70014","volume":"32","author":"B Risi","year":"2025","unstructured":"Risi, B. et al. Mitochondrial DNA (mtDNA) as fluid biomarker in neurodegenerative disorders: a systematic review. Eur. J. Neurol. 32, e70014 (2025).","journal-title":"Eur. J. Neurol."},{"key":"1274_CR202","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.nbd.2016.05.019","volume":"94","author":"P Podlesniy","year":"2016","unstructured":"Podlesniy, P. et al. Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson\u2019s disease. Neurobiol. Dis. 94, 10\u201317 (2016).","journal-title":"Neurobiol. Dis."},{"key":"1274_CR203","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/ana.24515","volume":"78","author":"A Pyle","year":"2015","unstructured":"Pyle, A. et al. Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson\u2019s disease. Ann. Neurol. 78, 1000\u20131004 (2015).","journal-title":"Ann. Neurol."},{"key":"1274_CR204","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105885","volume":"174","author":"M Puigr\u00f2s","year":"2022","unstructured":"Puigr\u00f2s, M. et al. Cell-free mitochondrial DNA deletions in idiopathic, but not LRRK2, Parkinson\u2019s disease. Neurobiol. Dis. 174, 105885 (2022).","journal-title":"Neurobiol. Dis."},{"key":"1274_CR205","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13024-020-00362-y","volume":"15","author":"H Lowes","year":"2020","unstructured":"Lowes, H., Pyle, A., Santibanez-Koref, M. & Hudson, G. Circulating cell-free mitochondrial DNA levels in Parkinson\u2019s disease are influenced by treatment. Mol. Neurodegener. 15, 10 (2020).","journal-title":"Mol. Neurodegener."},{"key":"1274_CR206","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105065","volume":"102","author":"M Puigr\u00f2s","year":"2024","unstructured":"Puigr\u00f2s, M. et al. Mitochondrial DNA deletions in the cerebrospinal fluid of patients with idiopathic REM sleep behaviour disorder. eBioMedicine 102, 105065 (2024).","journal-title":"eBioMedicine"},{"key":"1274_CR207","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ebiom.2019.09.015","volume":"48","author":"P Podlesniy","year":"2019","unstructured":"Podlesniy, P. et al. Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson\u2019s disease. EBioMedicine 48, 554\u2013567 (2019).","journal-title":"EBioMedicine"},{"key":"1274_CR208","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1093\/brain\/awaa246","volume":"143","author":"M Borsche","year":"2020","unstructured":"Borsche, M. et al. Mitochondrial damage-associated inflammation highlights biomarkers in PRKN\/PINK1 parkinsonism. Brain 143, 3041\u20133051 (2020).","journal-title":"Brain"},{"key":"1274_CR209","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22400-z","volume":"12","author":"M Asghar","year":"2022","unstructured":"Asghar, M. et al. Mitochondrial biogenesis, telomere length and cellular senescence in Parkinson\u2019s disease and Lewy body dementia. Sci. Rep. 12, 17578 (2022).","journal-title":"Sci. Rep."},{"key":"1274_CR210","doi-asserted-by":"publisher","first-page":"216.e7","DOI":"10.1016\/j.neurobiolaging.2015.10.033","volume":"38","author":"A Pyle","year":"2016","unstructured":"Pyle, A. et al. Reduced mitochondrial DNA copy number is a biomarker of Parkinson\u2019s disease. Neurobiol. Aging 38, 216.e7\u2013216.e10 (2016).","journal-title":"Neurobiol. Aging"},{"key":"1274_CR211","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3390\/genes12050720","volume":"12","author":"A Stoccoro","year":"2021","unstructured":"Stoccoro, A. et al. Mitochondrial D-loop region methylation and copy number in peripheral blood DNA of Parkinson\u2019s disease patients. Genes 12, 720 (2021).","journal-title":"Genes"},{"key":"1274_CR212","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2022.06.003","volume":"101","author":"AC M\u00fcller-Nedebock","year":"2022","unstructured":"M\u00fcller-Nedebock, A. C. et al. Increased blood-derived mitochondrial DNA copy number in African ancestry individuals with Parkinson\u2019s disease. Parkinsonism Relat. Disord. 101, 1\u20135 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1274_CR213","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3390\/genes14101913","volume":"14","author":"A Ortega-V\u00e1zquez","year":"2023","unstructured":"Ortega-V\u00e1zquez, A. et al. Longitudinal changes in mitochondrial DNA copy number and telomere length in patients with Parkinson\u2019s disease. Genes 14, 1913 (2023).","journal-title":"Genes"},{"key":"1274_CR214","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/mds.30098","volume":"40","author":"S Jo","year":"2025","unstructured":"Jo, S. et al. Mitochondrial DNA copy number as a potential biomarker for the severity of motor symptoms and prognosis in Parkinson\u2019s disease. Mov. Disord. 40, 502\u2013510 (2025).","journal-title":"Mov. Disord."},{"key":"1274_CR215","doi-asserted-by":"publisher","first-page":"e2683","DOI":"10.1212\/WNL.0000000000201288","volume":"99","author":"J Prasuhn","year":"2022","unstructured":"Prasuhn, J. et al. Assessment of bioenergetic deficits in patients with Parkinson disease and progressive supranuclear palsy using 31P-MRSI. Neurology 99, e2683\u2013e2692 (2022).","journal-title":"Neurology"},{"key":"1274_CR216","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1093\/brain\/awp293","volume":"132","author":"E Hattingen","year":"2009","unstructured":"Hattingen, E. et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson\u2019s disease. Brain 132, 3285\u20133297 (2009).","journal-title":"Brain"},{"key":"1274_CR217","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/brain\/awad364","volume":"147","author":"T Payne","year":"2024","unstructured":"Payne, T. et al. Multimodal assessment of mitochondrial function in Parkinson\u2019s disease. Brain 147, 267\u2013280 (2024).","journal-title":"Brain"},{"key":"1274_CR218","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1196\/annals.1427.037","volume":"1147","author":"C Henchcliffe","year":"2008","unstructured":"Henchcliffe, C. et al. Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson\u2019s disease. Ann. N. Y. Acad. Sci. 1147, 206\u2013220 (2008).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1274_CR219","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.594711","volume":"13","author":"J Guan","year":"2022","unstructured":"Guan, J. et al. Proton magnetic resonance spectroscopy for diagnosis of non-motor symptoms in Parkinson\u2019s disease. Front. Neurol. 13, 594711 (2022).","journal-title":"Front. Neurol."},{"key":"1274_CR220","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2025.10.014","volume":"588","author":"S Kumari","year":"2025","unstructured":"Kumari, S. et al. Neurobiochemical alterations in patients with idiopathic Parkinson\u2019s disease in sensorimotor cortex using 1H-MRS. Neuroscience 588, 1\u201310 (2025).","journal-title":"Neuroscience"},{"key":"1274_CR221","doi-asserted-by":"publisher","first-page":"s43586-022-0010","DOI":"10.1038\/s43586-022-00100-2","volume":"2","author":"C Pizzamiglio","year":"2022","unstructured":"Pizzamiglio, C., Vernon, H. J., Hanna, M. G. & Pitceathly, R. D. S. Designing clinical trials for rare diseases: unique challenges and opportunities. Nat. Rev. Methods Primer 2, s43586-022-00100-2 (2022).","journal-title":"Nat. Rev. Methods Primer"},{"key":"1274_CR222","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1126\/science.3201231","volume":"242","author":"DC Wallace","year":"1988","unstructured":"Wallace, D. C. et al. Mitochondrial DNA mutation associated with Leber\u2019s hereditary optic neuropathy. Science 242, 1427\u20131430 (1988).","journal-title":"Science"},{"key":"1274_CR223","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/331717a0","volume":"331","author":"IJ Holt","year":"1988","unstructured":"Holt, I. J., Harding, A. E. & Morgan-Hughes, J. A. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 331, 717\u2013719 (1988).","journal-title":"Nature"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01274-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01274-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01274-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:02:39Z","timestamp":1792756959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01274-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":223,"alternative-id":["1274"],"URL":"https:\/\/doi.org\/10.1038\/s41582-026-01274-z","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"21 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}